Introduction Patients at high bleeding risk (HBR patients) represent an important subset of
patients undergoing percutaneous coronary intervention (PCI). It remains unclear whether a …

Background: To date, it has not been ascertained whether shortening the duration of dual
antiplatelet therapy (DAPT) can benefit high bleeding risk (HBR) patients. This systematic …

Background Optimal dual antiplatelet therapy (DAPT) duration in patients at high bleeding
risk (HBR) is not fully defined. We aimed to compare the safety and effectiveness of short …

Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. We appraised an …

Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …

Previously we briefly reported the effect of 1-month dual antiplatelet therapy (DAPT) for
patients with high bleeding risk (HBR) receiving percutaneous coronary intervention (PCI) in …

Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …

Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy
(DAPT) in patients with high bleeding risk (HBR) undergoing percutaneous coronary …

Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention
(PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However …

Objectives To explore the impact of 6‐versus 12‐month dual antiplatelet therapy (DAPT) on
the clinical prognosis of high bleeding risk (HBR) patients. Background The optimal DAPT …